These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30142655)

  • 1. [Nutrition of horses with equine pituitary pars intermedia dysfunction ("Cushing's syndrome") treated with pergolid - A field study].
    Kienzle E; Bockhorni T
    Tierarztl Prax Ausg G Grosstiere Nutztiere; 2018 Aug; 46(4):249-256. PubMed ID: 30142655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).
    Donaldson MT; LaMonte BH; Morresey P; Smith G; Beech J
    J Vet Intern Med; 2002; 16(6):742-6. PubMed ID: 12465775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
    Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
    BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
    Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
    Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
    Rendle DI; Doran G; Ireland J; Edwards S
    Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pergolide treatment for Cushing's syndrome in a horse.
    Muñoz MC; Doreste F; Ferrer O; González J; Montoya JA
    Vet Rec; 1996 Jul; 139(2):41-3. PubMed ID: 8839490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide.
    Perkins GA; Lamb S; Erb HN; Schanbacher B; Nydam DV; Divers TJ
    Equine Vet J; 2002 Nov; 34(7):679-85. PubMed ID: 12455838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants.
    McFarlane D; Beech J; Cribb A
    Domest Anim Endocrinol; 2006 May; 30(4):276-88. PubMed ID: 16115743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide.
    Christen G; Gerber V; van der Kolk JH; Frey CF; Fouché N
    Vet J; 2018 May; 235():60-62. PubMed ID: 29704940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equine pituitary pars intermedia dysfunction.
    McFarlane D
    Vet Clin North Am Equine Pract; 2011 Apr; 27(1):93-113. PubMed ID: 21392656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Age, Season, Body Condition, and Endocrine Status on Serum Free Cortisol Fraction and Insulin Concentration in Horses.
    Hart KA; Wochele DM; Norton NA; McFarlane D; Wooldridge AA; Frank N
    J Vet Intern Med; 2016; 30(2):653-63. PubMed ID: 26860336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy.
    Banse HE; Whitehead AE; McFarlane D; Chelikani PK
    Domest Anim Endocrinol; 2021 Jul; 76():106620. PubMed ID: 33740552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary pars intermedia dysfunction: equine Cushing's disease.
    Schott HC
    Vet Clin North Am Equine Pract; 2002 Aug; 18(2):237-70. PubMed ID: 15635907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review.
    Tatum RC; McGowan CM; Ireland JL
    Vet J; 2020 Dec; 266():105562. PubMed ID: 33323174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.
    Rendle DI; Duz M; Beech J; Parkin T; Durham AE
    J Vet Intern Med; 2015 Jan; 29(1):355-61. PubMed ID: 25312676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PITUITARY PARS INTERMEDIA DYSFUNCTION (EQUINE CUSHING'S DISEASE) IN NONDOMESTIC EQUIDS AT MARWELL WILDLIFE: A CASE SERIES. ONE CHAPMAN'S ZEBRA ( EQUUS QUAGGA CHAPMANI) AND FIVE PRZEWALSKI's HORSES ( EQUUS FERUS PRZEWALSKII).
    Shotton JCR; Justice WSM; Salguero FJ; Stevens A; Bacci B
    J Zoo Wildl Med; 2018 Jun; 49(2):404-411. PubMed ID: 29900762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Equine Cushing's disease.
    Love S
    Br Vet J; 1993; 149(2):139-53. PubMed ID: 8485640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.
    McFarlane D; Banse H; Knych HK; Maxwell LK
    J Vet Pharmacol Ther; 2017 Apr; 40(2):158-164. PubMed ID: 27301465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The equine metabolic syndrome peripheral Cushing's syndrome.
    Johnson PJ
    Vet Clin North Am Equine Pract; 2002 Aug; 18(2):271-93. PubMed ID: 15635908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses.
    Innerå M; Petersen AD; Desjardins DR; Steficek BA; Rosser EJ; Schott HC
    Vet Dermatol; 2013 Feb; 24(1):212-7.e46-7. PubMed ID: 23331700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.